AST 487 is a potent and selective inhibitor of fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3), primarily utilized in cancer research and treatment development. It targets FGFR-driven cancers, such as lung cancer, bladder cancer, and breast cancer, where mutations in FGFR genes promote tumor growth and proliferation. Researchers use AST 487 to study its ability to block signaling pathways that affect cancer cell division and survival, thereby inhibiting tumor progression and metastasis. It shows potential for combination therapies with chemotherapy or other targeted treatments to enhance efficacy and overcome resistance. Currently, AST 487 is in preclinical stages, with ongoing studies to evaluate its safety, pharmacokinetics, and therapeutic potential for clinical trials in oncology.